VivoSeq
Gastroenterology

Cirrhosis of Liver

46

Pipeline Programs↗

0

Active Trials↗

29

Companies Involved↗

Cirrhosis of Liver is a moderately active landscape with 46 programs across 29 companies. The most active players are Zydus Therapeutics Inc., GSK, Viatris Specialty LLC. 26 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

0/100

Mech. Concentration

5/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Z

Zydus Therapeutics Inc.

1 program

Phase 1GSK logo

GSK

1 program

Phase 1V

Viatris Specialty LLC

1 program

Phase 1P

Phathom Pharmaceuticals, Inc.

1 program

Phase 2H

Horizon Therapeutics Ireland DAC

1 program

Phase 2EMD Serono logo

EMD Serono

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

45 of 48 classified programs — the dominant modality here.

6%ALL OTHERSProtein / enzyme24%Peptide12%

Small molecule leads; the ring shows all 48 classified programs, each share of the total. Modality classified for 100% of 48 pipeline programs.

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Unknown status1 · 33%

Clinical Trials

Trial Activity

Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2/3·NCT02451033·65 enrolled
N-Acetyl Cysteine in the Prevention of Contrast Induced Nephropathy in Cirrhosis of Liver-NEPHRO Trial
Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03759158·100 enrolled
Efficacy of Sildenafil in the Improvement of Cognition and Quality of Life in Patients With Cirrhosis of Liver. A Proof of Concept Study.
Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 1/2·NCT02028429·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)